CL2019000815A1 - Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928). - Google Patents

Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928).

Info

Publication number
CL2019000815A1
CL2019000815A1 CL2019000815A CL2019000815A CL2019000815A1 CL 2019000815 A1 CL2019000815 A1 CL 2019000815A1 CL 2019000815 A CL2019000815 A CL 2019000815A CL 2019000815 A CL2019000815 A CL 2019000815A CL 2019000815 A1 CL2019000815 A1 CL 2019000815A1
Authority
CL
Chile
Prior art keywords
ehmt1
ehmt2
amino
inhibitors
aryl
Prior art date
Application number
CL2019000815A
Other languages
English (en)
Inventor
John Emmerson Campbell
Kenneth William Duncan
Megan Alene Foley
Darren Martin Harvey
Kevin Wayne Kuntz
James Edward John Mills
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CL2019000815A1 publication Critical patent/CL2019000815A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE ARILO O HETEROARILO SUSTITUIDOS CON AMINO; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y MÉTODOS DE TRATAMIENTO DE UN TRASTORNO (E.G., ANEMIA DREPANOCÍTICA) MEDIANTE LA INHIBICIÓN DE UNA ENZIMA METILTRANSFERASA SELECCIONADA ENTRE EHMT1 Y EHMT2, ADMINISTRANDO DICHO COMPUESTO O DICHA COMPOSICIÓN FARMACÉUTICA A UN SUJETO QUE LO NECESITE. TAMBIÉN SE DESCRIBE EL USO DE TALES COMPUESTOS EN INVESTIGACIÓN U OTROS FINES NO TERAPÉUTICOS.
CL2019000815A 2016-04-15 2019-03-28 Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928). CL2019000815A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323602P 2016-04-15 2016-04-15
US201662348837P 2016-06-10 2016-06-10
US201662402997P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
CL2019000815A1 true CL2019000815A1 (es) 2019-08-16

Family

ID=58664786

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018002928A CL2018002928A1 (es) 2016-04-15 2018-10-12 Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
CL2019000815A CL2019000815A1 (es) 2016-04-15 2019-03-28 Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018002928A CL2018002928A1 (es) 2016-04-15 2018-10-12 Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.

Country Status (24)

Country Link
US (2) US20170355712A1 (es)
EP (1) EP3442947B1 (es)
JP (3) JP7041070B2 (es)
KR (2) KR102571679B1 (es)
CN (1) CN109153650A (es)
AU (3) AU2017250369A1 (es)
BR (1) BR112018071093A2 (es)
CA (1) CA3021062A1 (es)
CL (2) CL2018002928A1 (es)
CO (1) CO2018012181A2 (es)
DK (1) DK3442947T3 (es)
ES (1) ES2953512T3 (es)
FI (1) FI3442947T3 (es)
HU (1) HUE064145T2 (es)
IL (3) IL307931A (es)
LT (1) LT3442947T (es)
MA (1) MA44666A (es)
MX (2) MX2018012622A (es)
PL (1) PL3442947T3 (es)
PT (1) PT3442947T (es)
SG (2) SG10201913471VA (es)
SI (1) SI3442947T1 (es)
TW (1) TWI751155B (es)
WO (1) WO2017181177A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180017013A (ko) 2015-05-06 2018-02-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-Ras 조절제
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10179792B2 (en) 2016-03-07 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
US11278550B2 (en) 2016-05-17 2022-03-22 Duke University Compositions and methods for the treatment of Prader-Willi syndrome
US20200039998A1 (en) * 2016-12-19 2020-02-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
EP3600318A4 (en) * 2017-03-31 2021-06-09 Epizyme, Inc. METHODS FOR USING EHMT2 INHIBITORS
MX2019012532A (es) * 2017-04-20 2019-12-02 Univ California Moduladores de k-ras.
WO2018195450A1 (en) * 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
BR112020004112A2 (pt) 2017-08-28 2020-09-24 Enanta Pharmaceuticals, Inc. agentes antiviras da hepatite b
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN111343988A (zh) * 2017-10-17 2020-06-26 Epizyme股份有限公司 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
WO2019079540A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF
CN111343989A (zh) * 2017-10-18 2020-06-26 Epizyme股份有限公司 使用ehmt2抑制剂用于免疫疗法的方法
KR20200101332A (ko) * 2017-10-18 2020-08-27 에피자임, 인코포레이티드 혈액 장애 예방 또는 치료에 있어서의 ehmt2 저해제의 사용 방법
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
CN112334451A (zh) 2018-02-15 2021-02-05 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
AU2019342750A1 (en) 2018-09-21 2021-04-08 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020106816A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020224568A1 (en) * 2019-05-05 2020-11-12 Qilu Regor Therapeutics Inc. Cdk inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3163206A1 (en) 2019-11-27 2021-06-03 Riken G9a inhibitor
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
IL297845A (en) 2020-05-04 2023-01-01 Amgen Inc Heterocyclic compounds as a stimulating receptor expressed in myeloid cells 2 agonists and methods of use
CN111518015A (zh) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL311999A (en) * 2021-10-15 2024-06-01 Tango Therapeutics Inc New modulators of EHMT1 and EHMT2 and their therapeutic use
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024019541A1 (ko) * 2022-07-20 2024-01-25 일동제약(주) 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0585500A1 (en) * 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP1406875B1 (en) * 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
WO2003032994A2 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
NZ537752A (en) * 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
CN101031551A (zh) * 2004-07-06 2007-09-05 安吉永生物制药公司 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
AU2006336414B2 (en) * 2005-05-05 2011-11-24 Sanofi-Aventis U.S. Llc Stable nanoparticle formulations
CA2615420A1 (en) * 2005-07-15 2007-01-25 4Sc Ag 2-arylbenzothiazoles and uses thereof
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
US9018209B2 (en) * 2005-09-23 2015-04-28 Yale University Compounds and methods for the treatment of viruses and cancer
PL1951684T3 (pl) * 2005-11-01 2017-03-31 Targegen, Inc. Biarylowe meta-pirymidynowe inhibitory kinaz
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007140233A1 (en) * 2006-05-26 2007-12-06 Abbott Laboratories Inhibitors of polo-like kinases
CA2713716A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CN104230911A (zh) * 2008-04-16 2014-12-24 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
AU2009279825A1 (en) * 2008-08-05 2010-02-11 Targegen, Inc. Methods of treating thalassemia
KR20110049905A (ko) * 2008-09-03 2011-05-12 바이엘 크롭사이언스 아게 4-알킬-치환된 디아미노피리미딘
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
KR101531448B1 (ko) * 2010-06-04 2015-06-24 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서의 아미노피리미딘 유도체
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
KR101682417B1 (ko) * 2011-02-25 2016-12-06 주식회사유한양행 다이아미노피리미딘 유도체 및 그의 제조방법
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
WO2013033037A2 (en) * 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
KR101452235B1 (ko) * 2012-02-03 2014-10-22 서울대학교산학협력단 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
AU2013237226A1 (en) * 2012-03-19 2014-10-09 Emory University Quinazoline compounds and their use in therapy
GB201209613D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2903970A4 (en) * 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
WO2015109109A1 (en) * 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
CN106536509B (zh) * 2014-06-16 2020-06-09 基础应用医学研究基金会 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物

Also Published As

Publication number Publication date
KR102571679B1 (ko) 2023-08-29
JP7041070B2 (ja) 2022-03-23
PL3442947T3 (pl) 2023-10-02
MA44666A (fr) 2019-02-20
SG10201913471VA (en) 2020-03-30
CO2018012181A2 (es) 2019-08-20
CL2018002928A1 (es) 2019-02-01
BR112018071093A2 (pt) 2019-01-29
JP2022081606A (ja) 2022-05-31
AU2024200464A1 (en) 2024-02-15
PT3442947T (pt) 2023-08-07
AU2017250369A1 (en) 2018-10-11
TW201803854A (zh) 2018-02-01
LT3442947T (lt) 2023-09-11
DK3442947T3 (da) 2023-09-04
IL307931A (en) 2023-12-01
JP2019513778A (ja) 2019-05-30
JP2024045202A (ja) 2024-04-02
SG11201808799SA (en) 2018-11-29
FI3442947T3 (fi) 2023-08-24
CN109153650A (zh) 2019-01-04
MX2022010947A (es) 2022-09-21
US20170355712A1 (en) 2017-12-14
JP7420847B2 (ja) 2024-01-23
IL281319B1 (en) 2023-11-01
US20210198277A1 (en) 2021-07-01
IL262140A (en) 2018-11-29
MX2018012622A (es) 2019-08-29
EP3442947A1 (en) 2019-02-20
KR20230130747A (ko) 2023-09-12
AU2021245168B2 (en) 2023-10-26
EP3442947B1 (en) 2023-06-07
TWI751155B (zh) 2022-01-01
ES2953512T3 (es) 2023-11-14
SI3442947T1 (sl) 2023-10-30
CA3021062A1 (en) 2017-10-19
AU2021245168A1 (en) 2021-11-04
WO2017181177A1 (en) 2017-10-19
HUE064145T2 (hu) 2024-03-28
IL281319B2 (en) 2024-03-01
IL281319A (en) 2021-04-29
KR20180133906A (ko) 2018-12-17

Similar Documents

Publication Publication Date Title
CL2019000815A1 (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928).
CO2019006787A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos
ZA201906822B (en) Indole ahr inhibitors and uses thereof
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
MX2019015744A (es) Composiciones farmaceuticas.
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CL2015003569A1 (es) “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
EA201991073A1 (ru) Ингибиторы magl
CO2020012060A2 (es) Inhibidores de la arginasa
CL2021003105A1 (es) Inhibidores de masp-2 y métodos de uso (divisional de la solicitud no. 202003083)
EA201991074A1 (ru) Ингибиторы magl
EA201991029A1 (ru) Ингибиторы magl